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Panel Discussion:
Regulatory Perspective for Pathology Data
(Transcript)
In the 25th JSTP annual meeting at Hamamatsu on 28 January 2009
  The Japanese Society of Toxicologic Pathology (JSTP) held a symposium entitled “Panel Discussion: Regulatory
Perspective for Pathology Data” on Jan 28, 2009 during the 25th JSTP annual meeting at Hamamatsu (Jan 27–28,
2009) (Meeting President: Dr. Sunao Manabe, Daiichi Sankyo Co., Ltd., Medicinal Safety Research Labs).  The
purpose of the panel discussion was to clarify differences between USA, EU and Japan of 1) definition of
pathological data and 2) peer review process, and subsequently trigger their harmonization, by briefly introducing
the results of questionnaire survey conducted beforehand thanks to the cooperation of Japanese pharmaceutical
companies and contract research organizations. (This survey was conducted in cooperation with International
Federation of Societies of Toxicologic Pathologists/Regulatory Interaction Committee (IFSTP/RIC) and Japanese
Society of Toxicologic Pathology.)
  The panel discussion was co-chaired by Dr.Yuji Oishi (Astellas Pharma Inc.) and Dr. Kazutoshi Tamura (Bozo
Research Center). Panelists were Dr. Frédéric Schorsch (IFSTP/RIC, Bayer CropScience), Dr. Klaus Weber (Harlan
Laboratories, Inc.), Dr.Jerry Hardisty (Experimental Pathology Laboratories, Inc.) and Mr.Jun-ichi Kuranami (the
Japan Society of Quality Assurance, Kyowa Hakko Kirin).  During the panel discussion, simultaneous interpretation
-Japanese/English- was provided.
   This transcript of the panel discussion is published in the Journal of Toxicologic Pathology with the approval of
the 25th JSTP Meeting President and the board of directors of JSTP.
Moderator: Before we start the panel discussion, please
listen carefully to the instructions on the use of the
simultaneous interpretation receiver. Please place the
earphone on your ear and adjust the dial at the top of the
equipment to the channel of your preference. Channel 1 is
Japanese and channel 2 is English. Please use the orange
button on the side to adjust the volume. And now, we would
like to start the panel discussion, “Regulatory perspective for
pathology data.” Chairpersons Dr. Oishi and Dr. Tamura, I
leave the floor to you.
Dr. Yuji Oishi, Astellas Pharma Inc.: We would like to
start the panel discussion, “Regulatory perspective of
pathology data” of the last session of the 25th meeting of the
Japanese Society of Toxicologic Pathology. Allow me to
first introduce the panelists to you. Dr. Frédéric Schorsch is
the treasurer of the International Federation of Societies of
Toxicologic Pathologists (IFSTP) and member of the
Regulatory Interaction Committee. He is also the president
of the French Society of Toxicologic Pathology and is the
leader of the pathology group at Bayer CropScience in
France. Dr. Klaus Weber is the head pathologist at the
Harlan Laboratories in Switzerland. Dr. Jerry Hardisty has
joined us today from the Experimental Pathology
Laboratories, Inc. (EPL) of the United States. Last but not
least, our Japanese panelist is Dr. Junichi Kuranami from
JSQA, the Japan Society of Quality Assurance. We would
like to proceed with the discussion with the above four
panelists, myself, Oishi, and Dr. Tamura. (Slide 1–1)
There are two main topics to this panel discussion. First,
on the handling and use of digital data including those taken
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with digital cameras which are used quite frequently in
recent years. In particular, the discussion will focus on how
the digital image data are handled. The second topic of the
panel discussion is the peer reviews on pathology data,
especially given that there is great confusion in how they are
perceived in Japan. (Slide 1–2)
This discussion on pathology data images originated as
the position paper of the Society of Toxicologic Pathology
(STP) of the US, which was reprinted in the Journal of
Toxicologic Pathology at the beginning of this year. As those
of you who read the article already know, the position paper
itself was issued in 2007 with a statement that the American
College of Veterinary Pathologists (ACVP) and the British
Society of Toxicological Pathologists at the time gave their
full support and agreed with the general perspective of the
position paper. The Japanese Society of Toxicologic
Pathology (JSTP) would have followed suit and joined
others in expressing its agreement regarding the perspective
of the position paper as consensus for full support was
obtained at our board meeting in 2007, but did not meet the
deadline for publication. As such, we took the liberty to state
our full agreement and support regarding the position paper
in the latest issue of our Journal of Toxicologic Pathology
under the name of the President of the Japanese Society of
Toxicologic Pathology Dr. Tatematsu. (Slide 1–3) 
Now, I would like to hand the floor over to Dr. Tamura for
a brief explanation on its content. Dr. Tamura, please. (Slide
1–4)
Dr. Kazutoshi Tamura, Bozo Research Center Inc.: As
part of my role today, I would like to introduce the view of
STP regarding pathological image data as well as that in
Japan, while taking into consideration the results of the
questionnaire survey conducted by JSTP. First of all, I would
like to point out that the article partly quotes the basic
perspective of the position paper of STP. In the position
paper of STP, it describes what pathological image data and
their raw data entail. It is described in the position paper that
basically the pathological image data which are used as the
base for data generation are recognized as raw data, while
other data which are not used for data generation are merely
illustrative images and not raw data. (Slide 1–5)
Furthermore, it also defines the requirements of the raw data
and the raw data of the pathological images which were used
as the base for data generation. As there is a need to ensure
the integrity of the data in compliance with the GLP, one of
the requirements is to establish SOP. In addition, it describes
adding appropriate labels and signs, as well as determining a
standard storage method. When storing digital images,
authentication of the data must be conducted in compliance
with the electronic signature and part 11, and printed images
may be used. (Slide 1–6)
There are other pathological image data which may not be
used for data generation. Among those are illustrative
images which are required by the protocol and illustrative
images which are attached in the final report. These images
are not raw data, but they should be stored as documentation
of an action required by the protocol and preserved as the
illustrative images attached to the final report. Furthermore,
illustrative images submitted in a regulatory response are not
raw data, but these images are usually archived for
convenience. As for film photograph, authentication of the
data by printout used for data generation is thought to be
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more appropriate than by negative films. (Slide 1–7)
In response to this, I have quoted the GLP Guidebook
2008 for the general view in Japan. Various types of image
data are taken, but currently the observation form is defined
as raw data at many facilities, thus the photographs are
considered as reference materials. As such, it is said that
images taken by digital camera are considered as reference
materials. However, while considered as reference materials,
it says to enhance the procedures and records, conduct
thorough training and demonstrate the validity of the process
while following all procedures. At the same time, assure the
credibility of the image data, in particular its non-
falsification property. (Slide 1–8)
In recent years, various image data in addition to the
pathological data have been collected. When digital images
listed here are defined as data, it is said that one method for
securing their authenticity is to retain the data in media with
an electronic record and signature which is difficult to
modify. It is also said that another method for ensuring non-
falsification is to strengthen the system set out in the SOP,
records, operations and enhancement of education as well as
retaining the digital images as read-only data with
passwords. Currently, digital camera data cannot be aptly
stored in compliance with part 11. However, that does not
mean they cannot be made into raw data. (Slide 1–9)
Against such a backdrop, JSTP conducted a questionnaire
survey of 34 domestic institutions. The following are the
results of the questionnaire. The data had a valid response
rate of 29 out of 34. (Slide 1–10)  Firstly, as you can see in
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front of you, to the question “which photographs do you use
in the pathological examination?” most answered that the
materials they use are film cameras, and the use of digital
cameras is restricted to only a few institutions. (Slide 1–11)
When further asked, “Which photographs do you take with a
digital camera?” the response was that while they were
mainly for macroscopic images, they were also used for
microscopic data, in addition to electronic microscopic data
and image analysis. Nevertheless, they are still not all that
common. (Slide 1–12)
Let us now consider the position of “raw data”
photographs acquired with these digital cameras. As you can
see, the use of such data is very low and the use of those raw
data acquired with digital cameras is limited to certain
institutions at present. In particular, there are a few
institutions which only use digital data. (Slide 1–13)  In
addition, in response to the question on the use of digital
cameras, “What digital image data do you define as raw
data?” there was a response that, “The morphometric
analysis data including the images as the base for generating
the data are at times recognized as raw data at certain
institutions as well as those data recording other
representative illustrative images of changes.” (Slide 1–14)
Actually, more detailed questionnaires are being conducted,
but I believe that you now have a general picture of the
current status of pathological image data in Japan and their
usage. Other points I have described now are direct quotes of
the opinions and requests regarding the pathological image
data. (Slide 1–15)
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I have given you a brief outline of the perspectives of the
STP position paper and the Japanese government, as well as
the current usage of the digital data such as those taken by
digital camera in Japan. Therefore, I would like to ask Mr.
Kuranami to further elaborate on the view of JSQA as well
as on the various discussions on image data which have been
conducted over quite some time now in Japan. Please, I hand
the floor over to you now, Mr. Kuranami.
Mr. Junichi Kuranami, JSQA; Kyowa Hakko Kirin Co.,
Ltd.: As you can see before you, I would like to talk about
the use of digital images in the GLP study, as well as the
instructions from the authorities and the view of JSQA. As
has been introduced by both chairpersons just now, I have
been invited to this conference today as an executive
member of the group that is studying the GLP
pharmaceutical drugs at the JSQA. It is my great pleasure to
be invited here today. Thank you very much. (Slide 2–1)
Now, let me begin. Firstly, I would like to speak about the
instructions of the authorities, including the Pharmaceuticals
and Medical Devices Agency (PMDA), and the involvement
of JSQA until now. In front of you now is the chronological
outline of its history. As for digital images, PMDA issued an
instruction manual for the first time in 2001 and digital
cameras were practically not permitted for use from that
point. Since then, JSQA has been working to obtain the
permission for the use of digital cameras. We have made a
proposal for their use in May 2007. Discussions have been
held continuously with PMDA around the time, and the use
of digital cameras was conditionally permitted later in
September 2007 at the GLP training course. In the GLP
Guidebook 2008 that was issued the following year, it
provides a more detailed description on what makes raw
data. (Slide 2–2)
I would like to go into detail on the use of the digital
camera data which was first banned in 2001. Three points
were given by the authorities with a note “at present”. As
you can see before you, this was the general idea given by
PMDA. As such, it is difficult to define digital images as raw
data. It is also stated that they shall not be used in the final
report or even as a reference material. They all came with the
condition, “at present.” (Slide 2–3)
This led to the practical banning of the use of digital
cameras. Two major issues were raised by PMDA on the
report at the time, the major one being that digital images are
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extremely easy to edit on computers. The other problem was
that this modification procedure may be conducted without
leaving any trace. These two are extremely crucial issues,
which put in more sophisticated terms can be referred to as
the lack of authenticity, inadequate audit trail, etc. As such,
the trend led to the thinking of such data as basically not
being adequate for use.
On the other hand, however, I would first like to note that
the situation started changing around 2005. The Electronic
Records and Electronic Signature Guideline (ER/ES
Guideline) was starting to be established and the camera
market was becoming very active. At the time, there were
news that single-lens reflex camera for film will no longer be
manufactured. As for the basic medium, there was a market
trend to shift over to digital for all filming methods. As for
actual medical equipment, the cameras on the medical
equipment are all digital cameras now; thus such a change in
environment called for reconsideration of the policy. We
shared the same concerns as PMDA over the three points:
non-falsification cannot be assured, preservative quality
cannot be secured and the audit trail must be enhanced one
way or another. As such, we reviewed and discussed in
search of a solution to these issues. (Slide 2–4)
The conclusion we drew was as follows: development of
the procedures, enhancement of the records and provision of
thorough training. After all, what we came up with was in
general the same as what was written in the position paper.
We planned to cover for the disadvantage of digital images
which lacks GLP through taking this approach. In any case,
as digital cameras are not allowed for use in GLP studies, our
objective is first and foremost to obtain the approval for their
use. The ultimate goal, however, is to use them as raw data,
and a proposal has been made as such. (Slide 2–5)
In response to this, the policy issued by PMDA that same
year aimed to prove the validity of the process by having
well-trained employees keep the operation records according
to set procedures. The intention of PMDA was that the non-
falsification property of the data should be ensured through
such measures. Being able to ensure the non-falsification
property means that editing and modification of the digital
images after filming can be denied; thus, it was thought that
this should resolve the aforementioned issues. Regarding
this point, it was thought that the same procedures must be
effective for all raw data, therefore applicable to both
reference materials and raw data. That is how the use of
digital cameras practically became permitted. (Slide 2–6)
I would like to once again state the basic perspective of
JSQA I introduced so far. The focus is placed on the
thorough training of the personnel in charge, such as the
development of the procedures and the SOP. Furthermore,
audit trail is enhanced through taking records, as well as its
validity being ensured through such an approach. As such,
digital images now may be defined not only as reference data
but also as raw data, signifying that digital images could
most likely be considered as being like the so-called “paper
data” at this point, and thus accepted as such. (Slide 2–7)
And now, in the square at the very bottom of the screen
you will see the message that has been discussed ever since
the ministerial ordinance was revised last year. It states the
need to determine appropriate response measures at each
facility, operate based on their own decision and be able to
give adequate explanations. The message states that GLP is
not something that is imposed but instead something we
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create with our own hands. In short, we decide what we want
to do first, and then brainstorm what kind of approach we
should take. At the same time, it also states that while it is
extremely problematic if the plan is merely self-approving,
there is no need to be worried if an adequate explanation can
be made. As such, we consider it as something we create
ourselves. (Slide 2–7)  That is all, thank you.
Dr. Tamura: Thank you very much, Mr. Kuranami. I
believe we were able to deepen our understanding of the
current situation with the explanation given by Mr.
Kuranami, as he broke down and described the details in
chronological order. In contrast to such a situation in Japan,
I would like to ask the opinions of the panelists who have
joined our conference today. Please share with us the views
of your country and from your professional standpoint. First
of all, it would be our great pleasure if Dr. Schorsch of the
IFSTP could give us a brief overview of the situation in your
country. Dr. Schorsch, please. 
Dr. Frédéric Schorsch, IFSTP, Bayer CropScience:
Thank you. Concerning the digital images, we all share the
same difficulties. We have in Europe a discussion similar to
the one you have in Japan. For us, what is difficult today in
our different companies is to secure the electronic file and its
archiving according to GLP requirements. I think this is the
most difficult issue, because digital cameras and associated
software do not fulfill GLP requirements. The difficulty
concerns mainly the process of archiving. There are still
discussions to have such a system in place in our different
companies, and there is no standard defined by IT, QA or our
companies to deal with electronic data and electronic
images. There are different solutions, but the archiving of
raw data on paper is often the final choice. But is it
acceptable with images? As it was said in this meeting, the
local and company policies have to define how we have to
deal with the images. 
Dr. Tamura: Thank you very much. Dr. Schorsch has
kindly described to us now that the biggest problem probably
is ensuring the quality of the data preserved. And now, I
would like to ask Dr. Weber of Harlan Laboratories for some
comments. Dr. Weber, please.
Dr. Klaus Weber, Harlan Laboratories, Inc.: The major
problem that we encounter with archiving is that when we
have digital pictures we have to find a way to control if these
pictures are still running after two years or three years, or
something like this. We are especially asked from the Swiss
Medic to check our electronic data recordings every two
years, so this would increase tremendously the amount of
work that you are doing. We consider currently pictures only
as raw data when we use them for measurements and all
other pictures we do not consider as raw data; also, we store
them all in the same way.
Dr. Tamura: Thank you very much. Dr. Weber’s comments
just now, on how various data are checked every two years,
I believe that it certainly comes with great effort and presents
a real problem in reality. Next, I would like to ask Dr.
Hardisty of EPL of the United States for his input. Dr.
Hardisty, please.
Dr. Jerry Hardisty, EPL: Thank you. It seems to me that
there is not a lot of difference between the US position in
handling digital images as compared to the Japanese
position. The one area where there may be some differences
is whether illustrative images are considered raw data or not.
The STP position is that illustrative images are not
considered raw data; only those images, as Dr. Weber said,
where we obtain measurements are considered raw data.
When we do electron microscopy at EPL, even though the
image is taken with a digital camera we print a
photomicrograph, and that is the image that we use to
generate the data, so in that case the printed
photomicrograph would be raw data and not the digital file.
That is not necessarily true of morphometry. When you are
generating morphometry data, you do have to treat the digital
data as raw data. Some of the problems that we run into is
Part 11 compliance with some of the hardware and software
that is available in the United States. It is difficult to assure
that it is Part 11-compliant. The way we do that is exactly the
same way you do it in Japan, by ensuring that we have well
trained personnel, that we have SOP procedural methods to
assure that there is no possibility of falsifying the data, and
have an audit trail so that we maintain the original image as
well as any image that we may generate where we change
that image. We always keep the original image and an audit
trail, so I don’t really see too much difference between the
different areas (Europe and the United States and Japan) in
how digital images are being handled today, except with
illustrative images. 
Dr. Tamura: Thank you very much. As Dr. Hardisty has
mentioned just now, the question is what kind of digital
images may be defined as raw data. As I have explained
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briefly earlier and just as STP and JSTP have supported, and
thus in accordance with the basic stance of JSTP, raw data
are those used as a base for data generation. As for the
treatment of the illustrative images, however, the stipulated
range seems to vary slightly. In particular, my personal
impression is that common understanding on the range for its
use as reference material has not yet been fully established in
Japan. I would like to ask for a few words from our
chairperson, Dr. Oishi, regarding another situation in Japan
today, the current status of pharmaceutical firms in Japan. I
think this will give us a wider perspective. Dr. Oishi, please.
Dr. Oishi: As we are engaged in morphology, it goes
without saying that we collect various images as part of our
daily routine. Fundamentally, these data should just be
stored with a report, but it requires a lot of energy when
storing the raw data in accordance with the regulations we
have been discussing so far. In addition, the photographs are
not taken as a direct material used in studies but merely as
reference data; thus, in most cases photographs are merely
taken as so-called “typical examples.” As explained earlier,
an instruction to “save reference data just like any raw data
for GLP” is very abstract and vague in Japan has been caused
a very serious problem in reality. That is where we feel that
digital cameras are extremely difficult to use in GLP studies.
It seems that such regulations are hindering the digital
camera images from being used as a material for
supplementary data to improve the quality of the study. 
On the contrary, for example, the electronic microscopes
that we use at our facility have a digital camera and a digital
television installed, but we are observing the television and
directly recording our findings. Normally, photographs are
taken first and then findings recorded while observations are
made from these photographs, but there are some cases
where photographs are not taken (due to the regulation
regarding digital data). In general, it is best to photograph the
findings, but the various procedures stated before to fulfill
the regulations of the digital data are extremely complicated
and require a lot of energy. The problem that Japan is faced
with currently, therefore, is that the standard for which data
must be actually stored and the cutoff line from where they
do not need to be stored is very obscure. I feel that the border
is extremely ill-defined as to what should be stored, and as a
result the cutoff line seems to be established at a lower level
because of accepting compromise plans. That is all, thank
you.
Dr. Tamura: Thank you very much. As discussed just now,
I would like to ask a few words from Dr. Hardisty on how to
handle data as the so-called “reference data.” How are those
image data attached to a final report handled? And also, how
are they stored, or are they not stored at all? It is briefly
mentioned in the position paper, but I would like Dr.
Hardisty to give us a few words on the current situation on
this point.
Dr. Hardisty: I was not involved directly in the drafting of
this document by STP, but I think that STP proposes that
those illustrative images that are included in the final report
are not raw data. They are just illustrations of a particular
lesion, and no data is generated from those. It is a photograph
used to demonstrate what something looks like, but it is not
actually considered raw data so it would not be handled as
raw data.
Dr. Tamura: Thank you very much. In other words, could
we take you to mean that there is no need to store the object
itself?
Dr. Hardisty: I think that they are archived along with the
final report, but they are not required to meet the Part 11
compliance process, but the image would be archived with
the final report in the raw data. 
Dr. Tamura: Thank you very much. I believe that point is
very easy to understand for us on the Japanese side as well.
Dr. Weber and Dr. Schorsch, are there any points that you
find different between your countries and Japan in
particular? If you do, please share them with us. Dr.
Schorsch, how about you?
Dr. Schorsch: I think that the position explained by
Dr.Hardisty is exactly the one we face in our different
companies. The illustrative photographs are not considered
to be raw data. What has to be considered as raw data is the
diagnosis and the final conclusion made by the study
pathologist after his evaluation. Illustrative photographs can
help and support this conclusion. But there are few
toxicologists who can really interpret such photographs. You
must have the skill of a pathologist to interpret such
photographs and there are few pathologists within the
different authorities. Furthermore you know that it is
impossible to make a complete evaluation based only on
pictures which reflect only a small part of the slide and do
not take into consideration the whole animal and all the
observations found in all animals belonging to one group.
Clearly, illustrative photographs are not very useful from the
pathologist point of view. What is important is the
conclusion written and signed by the study pathologist.
Concerning the electron microscopy or the cell proliferation
studies, it is clear that those photographs are raw data, and
we have to store and to archive them. As I said before, the
problem we have today in our different companies is how we
can guarantee the security of these files for a long period of
time. I am working in the agrochemical industry and we have
to keep this data as long as possible, and of course during the
life time of the compound, and today IT systems do not
guarantee that we can open this file again after a long period
of time. This is why we are not completely clear with
electronic data. 
Dr. Weber: I can just support this opinion, because we are
using the photographs as a type of explanation in a report;
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We sign the report and this report is the original raw data
along with the slide used for taking the photograph. We
consider the slide as an original subject and we can make
another photograph if necessary, so it would not make a lot
of sense to use these illustrative images as raw data. 
Dr. Tamura: Thank you very much. That was very
interesting. I believe raw data is actually clearly defined at
each facility. As mentioned earlier, even when some data are
actually used as raw data, I believe the issues we have
discussed thus far are something we must continue to tackle
instead of trying to study and uncover the relation between
raw data and its preservation quality right now. While I feel
this issue is something that should not call for such a big
debate, I believe that through various opportunities the
vague boundaries will be determined through discussions,
such as among those institutions in Japan in particular that
are responsible for handling reference data. I believe that the
way these digital data should be handled is starting to take
concrete form through the various opinions shared today by
Dr. Schorsch, Dr. Weber, Dr. Hardisty, Mr. Kuranami and
Dr. Oishi. As we have two topics scheduled to discuss today,
we would like to end the discussion on the digital data issue
for now. Let us now move onto the session on peer review.
Dr. Oishi, please.
Dr. Oishi: Now I would like to start our discussion on
pathological peer review. (Slide 3–1)  First of all, I would
like to describe briefly the basic perspective of the position
paper that has been brought up quite often so far. The basic
perspective of the position paper on reviews, whether
official or unofficial, which includes those that are
sometimes referred to as “sponsor reviews” in Japan, is that
it is to be conducted before the data has been finalized. I
believe this is the most different point from the procedures
practiced in Japan. The position paper provides that the
records and explanatory notes regarding the review are all
part of the intermediary notes of the personnel in charge of
pathological findings; thus these notes need not be stored. In
case of an official review, differences in the interpretation of
the findings among the pathologists are resolved first, and
then written down in the statement of the peer review that the
review has reached an overall agreement. This statement is
normally then included in the final report. This is the basic
procedure outlined in the position paper. (Slide 3–2)
The view in Japan is that basically its definition of raw
data practically meets the international standard described in
the position paper. The understanding is that raw data is
something that is finalized after the pathologists make
decisions, fiddle the information around in his/her head or
change the findings. As for the changes made after the data
has been finalized as raw data, it states that all changes must
be recorded. I feel that this part of the procedure is mostly
consistent around the world. (Slide 3–3)
The biggest difference between the Japanese practice and
the international standard is regarding the “sponsor review.”
While “sponsor review” is a name used which is unique to
Japan, example procedures were found in the GLP
inspection conducted for a Contract Research Organization
(CRO) in 2006. The inspection revealed that a sponsor
review was conducted upon drafting a final report on the
pathological findings, where some of the findings were
modified. Despite such modification, however, the places
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that were modified and the reason for such changes were not
recorded in the final report. Because of this, the
aforementioned sponsor reviews on histopathological
examination are now to be conducted after the findings have
been finalized. Moreover, in case of conducting a sponsor
review, all records must be kept, while the reason and
content of the modification or change if any must be
included in the final report. These instructions have been
given in Japan, and the participants were advised to do so at
the GLP training seminar in 2007. (Slide 3–4)
In Japan, histopathological data is finalized before the
review. As for Europe and the United States, however, the
reviews are basically viewed as a process conducted to
finalize their findings in reports, including the position
paper. In short, the timing of the review differs. Furthermore,
as mentioned by Dr. Weber just now, the pathological report
exists in Europe and the United States. This in Japan again is
slightly different. According to the instructions given by the
Japanese authority, the general understanding is that reports
shall be written by SD and those written by someone other
than SD are not considered as a report. It is also not a
common practice in Japan to attach signed pathological
reports to the final reports. (Slide 3–5)
As for the questionnaire results regarding the question
whether they are conducting a peer review of any form,
including external sponsors and/or internal parties, the
majority of the people responded that they are conducting
peer reviews. (Slide 3–6)  As for the type of reviews, the
most common response was internal peer review. As it will
amount to an immense number of reviews when conducting
both reviews (internal and external), therefore, pathologists
in the same laboratories are made to conduct reviews on each
other first. The responses also revealed that most studies are
constantly under internal review, and also that most of the
cases are external review when only a partial review is being
conducted. Sponsor review is the next most common type of
review conducted according to the responses we received.
(Slide 3–7)
The next question was on what kinds of studies the
reviews are conducted on. The responses showed a similar
pattern for studies between three to six months. Basically the
most common type of review conducted was internal
reviews as mentioned earlier, followed by sponsor reviews.
Cases of external reviews are very minor. On the other hand,
the responses stated that reviews of most carcinogenicity
studies are conducted as external reviews. The second most
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common type of review is the sponsor review, which proves
that in any case sponsor reviews are actually conducted very
frequently. (Slide 3–8)
Regarding the question on the timing when the reviews
are conducted, the results of the responses were reflective of
the administrative instruction. In case of internal reviews,
conducting it prior to fixing the findings is the most
commonly practiced style. In case of sponsor reviews and
external reviews, however, responses showed that the
majority of the people follow the guidelines of PMDA, and
they are conducted after the findings are fixed. (Slide 3–9)
As for the question as to whether they are saving the
pathological reports when revisions are made, there were
unexpectedly many who answered “only those after
revisions.” Many responded that, “Only a revision record
after has been saved”, while PMDA instruct record to be
made every step, we only record after a revision has been
made.” There are, however, people who keep records both
before and after a revision. (Slide 3–10)
Another question asked was in case of a revision being
made to a finding, where will the reason to the modification
be recorded. The responses we received were, “basically on
the raw data,” while the PMDA instructs records to be
included in the final report. Basically it is most common that
the records are kept on the raw data. The next common place
was the ledger sheet (Table/Appendix), followed by the final
report. There were responses that stated they do not keep any
record. (Slide 3–11)
Next, to the question of whether they attach the statement
of a peer review as it used in Europe and the United States,
there were many cases where these statements were attached
in external reviews. In some cases, however, there were
responses that they do not attach such statement. (Slide 3–
12)
Then the next question was whether they record and
attach a list of all changes made to the final report. The most
common response we received again was that they do not
practice this procedure. The result was the history of changes
are hardly ever recorded for external, sponsor or internal
reviews. (Slide 3–12)
Other comments left in the blank space provided in the
questionnaire included the following. The principle provided
by the institutions was not actually to reflect the history of
changes and other revisions in the final report but to clarify
the history of modification made by a peer review. As such,
there were cases where modified parts were marked in the
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ledger sheet. Another comment said that an internal review
was not the equivalent of a peer review. However, there was
also a comment that conducting a sponsor review prior to
fixing the pathological findings is inappropriate. There is an
instruction that a sponsor review shall be conducted after all
findings have been fixed. The above is the situation in Japan.
(Slide 3–13)  I would now like to ask Mr. Kuranami to share
with us the views of QA.
Mr. Kuranami: As has been discussed so far, I would like
to talk about the instructions given by the authorities and the
views of JSQA on sponsor reviews. (Slide 4–1)  I will be
talking in chronological order just like earlier, but just to
give you an outline, I would like to state the following. It is
rather a relatively old topic, but when looking back at its
history, the definition of raw data in pathology started to
form its outline in 1997. In response to this development, the
definition of a raw data of pathological examination was first
determined in what is known as an instruction manual, GLP
Handbook of Pharmaceuticals 1997, which has been around
for quite some time now. Its content is as how Dr. Oishi has
explained just now. I will go into details later. The
instruction manual GLP Handbook of Pharmaceuticals and
Chemicals was renewed in 2002, while its content virtually
remained the same as the 1997 edition.
The next development was, as explained earlier by my
fellow panelist, the prohibition of conducting sponsor
reviews which was brought up at the GLP training course in
September 2005. After that, we come back to the following.
GLP Handbook of Pharmaceuticals and Medical Devices,
Vol.1 was published in October 2008, but basically the
contents of all three editions are the same. That means that
even after sponsor reviews were prohibited in 2005, the
definition of raw data has remained the same as that in 1997.
At the very end of the list, there is a question mark printed
after March of this year where volume 2 of the publication is
scheduled to be released. I have been told that its content
would most likely be what sounds like a collection of Q&As.
I am hoping that a new description on how sponsor reviews
are to be handled will be provided in this new publication.
(Slide 4–2)
Let us now look at the details in chronological order. As
we had Dr. Mitsumori kindly share with us about the raw
data of the pathological examination in 1997, the raw data of
pathological examination is different from those of other
examinations. As for the pathological data, they are the
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finalized data and was clearly stated that these are to be
defined as raw data. There were two other messages he has
shared with us which were: data are to be finalized as raw
data first in the case of requesting an opinion of someone
outside of the GLP; and, there are possibilities of the
findings being altered drastically by the sponsor in extreme
cases when opinions are requested to a third party before the
said data are finalized. (Slide 4–3)  In the GLP Handbook of
Pharmaceuticals published the following year in 1997,
however, five points were listed as the main messages in the
manual. These points included that one may get closer to the
truth after examining all slides microscopically and re-
examining the findings. Another point mentioned was that
conclusions are most appropriate to be drawn not from the
initial findings but from the finalized findings. As such,
procedures for modification in the raw data are necessary in
making the changes in the finalized findings. Obviously, the
procedures for modification are required to be followed
appropriately. (Slide 4–4)
Although a topic of a slightly different tone, it comes
down to predetermining who will hold responsibility for the
finalized findings. I believe this is being commonly
practiced now. On a different note, or rather a slightly
different subject, there are opinions that it is preferable to
record all the procedures up until the finalization of the
findings. As “preferable“ in Japanese legal terms can be
interpreted as “pretty much do it,“ thus realizing something
that is written as “basically preferable“ could be extremely
difficult. Actually, however, I believe that keeping records
of such procedures is hardly ever practiced at present.
For a while new pathological views were not shown, but
the topic of sponsor review as discussed by Dr. Oishi just
now was brought up in 2005. That is when conducting
sponsor reviews after the pathological findings have been
finalized became a huge topic of interest. It was also stated
that records must be kept that a sponsor review was
conducted and that its reason and contents be recorded in the
final report if a pathological finding was to be revised as a
result of conducting the sponsor review. In short, the
instructions were to conduct a sponsor review on the
finalized pathological findings, as well as to keep records of
all changes in the sponsor review and to write them down in
the report. Behind this or rather at the core of these
instructions was the concern over a space for reasonable
doubt that the sponsors may have changed the findings given
that the record of changes made to the pathological findings
are not kept prior to its finalization. It is called “sponsor
power,” and it is understood that these instructions were
given as the possibility of such power intervention cannot be
denied. (Slide 4–5)
And as for the perspective of JSQA, we have indicated
our view to PMDA last September. What I mean by that is,
in light of the second volume of the instruction manual we
are planning to publish this March which I mentioned earlier
about, we have reviewed over 350 Q&As in total in the
guidebooks published between 2003 and 2008, and have
added necessary comments upon submitting it to PMDA.
Sponsor review was one of the topics we covered.
The problems concerning sponsor reviews are as I
described earlier, that no records are kept until the findings
are finalized and the possibility of the sponsor power
working cannot be denied. We also recognize that the
problem also lies in the possibility that changes are
unintentionally made as a result of such factor. There are,
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however, views that the sponsors are after all not the source
of all evil. I wonder why we tend to brand the sponsors as a
bad influence, and so we are actually hoping to get rid of
these bad rumors if possible. Before you presented the two
major reasons as to why it is necessary to get rid of such a
negative image. The sponsors should have the most amount
of information on the test article. In addition, they should be
the ones who are most aware of the findings that might
appear by applying the said test article and the changes that
arise from its application. There is an extremely high
possibility of determining the incorrect findings as the final
data if we cannot discuss with such people before finalizing
the findings. I also believe that this leads to an extremely
high possibility of reducing the quality of the study all
together. (Slide 4–6)
The view of JSQA regarding the sponsor review and its
nature is that there should be no problem in conducting them
prior to finalizing the findings. However, the point is this.
The findings become raw data only after they have been
finalized, but we believe that it might be better to record all
findings and changes made from before they are finalized.
Through such practice, we believe we can alleviate some of
the concerns we now face. We have submitted this view to
PMDA so far and have expressed our wish for the
prohibition on the sponsor review which has been in place
for some years now to be lifted. However, we have not yet
received an official or public response from PMDA on this
point, so we do not know if our opinion will be accepted or
denied. I would like to state that this is the view of JSQA.
(Slide 4–6)  That is all, thank you.
Dr. Oishi: Thank you very much. And now, I would like to
ask Dr. Schorsch of the IFSTP to discuss about matters in
this area next.Dr. Schorsch, please. 
Dr. Schorsch: Thank you very much. I would like to thank
Dr. Manabe for his kind invitation. It is a pleasure for me to
be here in your fascinating country. We have a lot of
experience to share. I would like to thank the Japanese
Society of Toxicology Pathology, for having addressed this
issue at the international level. As an IFSTP representative
and officer, we were pleased that we were contacted to deal
with this topic and we have organized a group with one
representative for the United States, with Jenny Mackay, one
representative for the Japanese with Dr. Manabe, and one
representative for Europe with Dr. Catherine George. I
would present some results of our understanding of what it is
done at least in Europe and the United States. (Slide 5–1)
I think that there is a clear understanding of what we do,
because we are all pathologists, and we do daily the same
job. 
First we have a consensus for the need of a pathologic
peer review. The study pathologist is the unique scientist
who has to create his own data in the toxicology study. He
has to be helped. The goal of the peer review is to add the
experience of one’s peer pathologist, to secure the data, and
to add some expertise to this first analysis. Furthermore, the
peer review process has to bring some standardization,
harmonization if needed, and of course some training, but
the main goal is to give security, accuracy to the conclusion
of the study and expertise on the pathological data. We are
well aware that there is potential influence on the data, but
for us, since the peer review is done by one’s peer who is a
true pathologist, bringing his own expertise, we do not
question the need of such process. (Slide 5–2)
Secondly, there is a consensus on how the peer review
must be conducted. There are a lot of papers explaining how
it has to be done. Dr. Hardisty and other colleagues have
published a long time ago a very detailed paper with best
practices, explaining how a peer review has to be conducted.
We can make the difference between different types of peer
review: In some papers we speak about “formal,”
“informal,” “sponsor,” but for us there is one type of review,
the peer review done by a pathologist for adding accuracy to
the produced data by the study pathologist. (Slide 5–3)
Then there has to be a consensus on interim notes for
pathology data: the interim notes (that the study pathologist
needs to build his interpretation) are not raw data. It is well
recognized by US authorities, the Food and Drug
Administration (FDA), the Environmental Protection
Agency (EPA), and it is clearly stated—and it is the same in
Europe—that we need some interim notes to construct our
study. We can change our data until finalization. The
changes we do during the peer review are included into this
process, because the peer review is to help, again, to give
more accuracy to the data we  generate. (Slide 5–4)
There is a clear consensus of the workflow for the
generation of the pathology data, there are first some interim
notes. The data are not finalized, the data are not locked at
this stage. We do the peer review, whatever the type of peer
review you want: informal, formal, sponsor peer review.
During the discussion you can change your data, and
afterwards you finalize the data. Then you can produce a
report, a pathology report which has to be signed, or the
whole toxicology report, both of them have to be signed by
the study pathologist. If changes come after this signature,
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then all changes have to be audited of course, as it has been
described before. (Slide 5–5)
For us, there is again a clear consensus of what is a
pathology peer review. It is not an audit. It is a discussion, a
discussion between two pathologists, as we do daily when
we show some slides to our colleagues. The second
pathologist must normally be more experienced, and since a
discussion is always positive, it must be considered as an
external help. If there is some discussion or problem with
interpretation, this face to face discussion will help to resolve
the issue. If there are still some difficulties, you can ask for a
third party, a third pathologist, or a pathology working group
whatever you call it . You can lock the data before or after.
But if they are locked, you must justify the changes. If not, it
means that the discussion process is not finished and that you
are still working on interim notes. (Slide 5–6)
So in conclusion, for us the peer review has to be
conducted before finalization of the data, and since these
changes or discussion are considered to be interim notes,
they are not considered to be raw data; they can be
documented and kept. They are not considered to be raw
data, and they have not to be presented to the auditors. (Slide
5–7)  For me, I think that that there is a problem of definition.
Thank you very much.
Dr. Oishi: Thank you very much. There is a difference in
opinion at an international level between the Japanese
agency and the Society of Toxicologic Pathology, but first of
all, I must say that “sponsor review” is not a term used in
other countries. Nonetheless, I would like to know how
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much they are conducted. Could Dr. Klaus Weber from the
CRO in Europe kindly share with us the situation in Europe?
How much sponsor reviews are actually conducted?
Dr. Weber: We have quite a lot of peer reviews performed
by sponsors. How we handle the situation is, within our
pathology department I take care that every study of four
weeks and longer will be peer reviewed internally. In
Europe, we have a guideline that is asking us specifically for
a peer review for carcinogenicity studies performed in
pharmaceuticals. This guide is from the EMEA. EMEA
expect that we do such a peer review in such a type of
studies. But this is the only regulation we have. This
regulation is dealing with a minimum of what you have to
do. It is telling you at least 10% of the tumors, and at least
10% of the animals per group. But this is a recommendation.
We are able to make more of these things. Again, a sponsor
peer review in the CROs as in Japan is in Europe, a common
situation.
Dr. Oishi: Thank you very much. How about in the United
States, Dr. Hardisty?
Dr. Hardisty: I think the situation in the United States is
very much like the situation is in Europe. The study
pathologist has a very strong position in the generation of
pathology data. In the United States I understand the study
director in Japan is the one who writes the report, but in the
United States, the study pathologist has to write the
pathology report. The study pathologist is the only one that
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can finalize the pathology data. When we do peer review in
the United States, we always do it on draft data. We do it
before the study pathologist finalizes the data, and we act as
consultants with the study pathologist to come up with the
most accurate data that we can for this study. In a formal peer
review, we are trying to achieve two things. One is to
increase the accuracy, but also to increase the confidence
that a study sponsor or a regulatory agency has in the data.
We also approach it in a manner where we are trying to make
sure that all target tissues have been identified, that the data
is using current nomenclature and diagnostic criteria, and
that the correct no adverse effect level (NOAEL) has been
identified. So a peer review, a formal peer review, is a very
involved process where you are working with the study
pathologist to finalize the data. The study pathologist though
is the only person who can actually change the data. The peer
review pathologist acts as a consultant to advise the study
pathologist. 
I have never had a situation where I could not work with
a study pathologist to come up with a consensus in the
diagnosis, and we have never had to go to a pathology
working group to resolve these. It has worked very well. I
think that the quality of the data when we are done with peer
review is excellent. In the United States, the FDA does not
have a guideline for requiring peer review. They do not
require peer review. But they do like to see studies submitted
to them that have been peer reviewed, because it gives them
extra confidence in the data. I do not think that there is a
concern by our regulatory agencies over sponsor influence
on the peer review, because I think they understand that it is
two scientists working together to come up with the best set
of data for the regulatory agencies to make their decisions
on.
Dr. Oishi: Thank you very much. Have there been any
discussions made regarding “sponsor power” at IFSTP?
Dr. Schorsch: No, I think it is exactly what was explained
by Dr. Hardisty. We do not make such a difference, because
for us, the peer reviewer must be an experienced pathologist,
and his goal is to increase the accuracy of the data, and give
his expertise. There is no problem, it can be internal, it can be
external, it can be a sponsor peer review. What is important
is that the peer review is conducted by a skilled pathologist,
and that he gives an input and help to the initial pathologist.
That is the goal of the peer review. Whatever you call it, it is
to increase and make the evaluation better, and each
company responsible for the data understands that. As Dr.
Hardisty said, although I am a little bit younger but I have
never seen difficulties to resolve the differences if they are
there between two experienced pathologists. We understand
that we do a difficult job; we know that. We understand that
we have to prepare a unique set of data, of course. We have
to be clear, and responsible. There is never a problem to
finalize the data after the peer review.
Dr. Oishi: As Dr. Schorsch is also at the manufacturing firm
of Bayer, how much review do you actually conduct as a
sponsor? What is the general stance of the corporations in
Europe?
Dr. Schorsch: Yes, we have occasionally some sponsor
review, and there is no problem; it may be a problem if the
pathologist mandated by the sponsor has limited experience.
But it is the responsibility of the company to select the good
expert, because we have to produce the correct data. In
agrochemical industry, since the data generated during the
development will serve for the risk assessment without
studies in humans, it is necessary to trust the data we
generate. For us and for me, it is clear: we have to select
internally or externally, whatever we want, an experienced
pathologist to do this task; and in the raw data, what is
important is to include the name of the study pathologist. As
you may know, at the IFSTP level, we are now discussing an
international system of recognition for study pathologists,
because in this peer review process, it is very important to
bring expertise. If you do not bring expertise, the peer review
is not necessary, and I completely understand the US
situation where it is not regulatory or mandatory. But if you
do the process, you have to bring some additional expertise
to your review.
Dr. Oishi: And now, I would like to ask Dr. Tamura for his
insight on the practices in Japan as I believe he has great
understanding of the current situation. Are they conducted
pretty frequently like in other countries?
Dr. Tamura: Well, that is true. We receive a number of peer
reviews from our sponsors. However, regarding the question
of problems arising due to the pressure from the sponsors, I
believe it cannot be simply identified as a problem. This
again as discussed by Dr. Schorsch just now, speaking from
the standpoint of a CRO and as a study pathologist myself, it
is also true that having contact with sponsors provides us
with a great opportunity to obtain as much information as
possible. As such, I believe it is extremely preferable to
utilize such opportunity to collect more high-quality real life
data. Of course, depending on who they are, in particular
young study pathologists may feel as if he/she is under
pressure when an opinion is voiced by a third party, but I also
think this may be limited to a few. I believe that what we can
gain is far greater than such downsides.
Dr. Oishi: Thank you very much. As from this discussion
now, I believe that you here are all under the impression that
the sponsors do not pose that much pressure on the
pathologists and are not a realistic threat. As we all practice
pathology, I think we all believe in each other that none of
our fellow pathologists will sell out our consciences and
hearts, yielding to such power. To the contrary, as proposed
by JSQA, the general stance is to practice a more open
procedure if there is no such pressure from the sponsors. As
stated by Mr. Kuranami on the standpoint of QA in Japan
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keep records more in an open manner in the effort to prove
that there is no forced modification of data or pressure from
the sponsors. Any thoughts on the point discussed just now?
Mr. Kuranami: Speaking from a scientific point of view,
sponsor reviews and reviews in general are indeed very
important. When considering the factors that are impeding
the reviews, I believe “sponsor power” is a factor that cannot
be ignored. If this problem can be resolved and effective
reviews may be conducted, then I believe it is in our best
interest to consider what we can do to resolve this setback.
And I think one of the proposals drawn from such thought is
to start by keeping records as I have just mentioned. I would
like to see this happen more now that I have heard you
exchange your views today.
Dr. Oishi: On that point, Dr. Hardisty, what would you say
if there was a proposal to practice procedures in a more open
manner since the discussions in Europe and the United States
have nothing to hide?
Dr. Hardisty: It is a different approach than we have in the
United States. It varies. If we finalized our data, as you do in
Japan before the peer review, then that is the way we would
have to do it. Occasionally we do have peer reviews of
finalized reports in the United States. When we do that, we
have to keep the records, and the study pathologist then,
though, has to prepare an amended report, so there are two
reports now. That is what we are trying to avoid. We are
trying to make this a streamlined process. The raw data is
defined as the signed final report by the study pathologist,
and if the glass slide is the specimen that raw data has been
generated from, then there is no feeling that we have to put it
in this documentation. The problem with the documentation
is not the document itself; it is what it is going to be used for.
I have only two times in the last 30 years had the FDA asks
for the documentation. In both instances, it was multiple
study pathologists reading the study, so they were concerned
about consistency in the data and what was done. Rather than
use this to help understand the process, the FDA started to go
down one discrepancy after another and wanted to know
why. The FDA’s compliance officer was in the room at the
time. His statement was that the FDA had no authority to ask
for these documents, because it is not part of the regulation.
So in the United States, the FDA does not want to see these
documents. They want a clean, final report signed by the
study pathologists, which represents the raw data.
Dr. Oishi: Regarding this point, Dr. Weber, how is it in
Europe?
Dr. Weber: We have exactly the same situation as in the
United States, but I have another concern. For me, it is hard
to understand. As Kuranami-san said, of course a sponsor
review will be well accepted in front of a scientific
discussion, but when your government is even asking for a
peer review, and you are concerned that a scientific
discussion between a sponsor and a pathologist is a good
way to increase the accuracy of the studies, then in the case
you want to influence a person, intimidate a person, you can
do it also in this way. So it has nothing to do, in my opinion,
with the peer review. On the other hand, as Tamura-san said,
when someone is telling the young pathologist, and they
could be becoming intimidated, the young pathologist has
obviously also a head of pathology, and if my pathologist
would become intimidating for my client, I would take this
into my hands and then we would rule this out.
Dr. Oishi: Dr. Schorsch, any thoughts on that point? Do you
have any thoughts or points to discuss regarding this?
Dr. Schorsch: I think that I understand the issue, but as you
have said, we are all pathologists; we have the same
difficulties, and we all agree that there is a need for
discussion to improve our data. This discussion between two
pathologists, which takes place during the peer review, has
to be done, and the problem of the influence is again not a
problem if it is a good influence. There is an influence; a peer
review of course is a discussion and the peer reviewer will
influence the data. But that is the role of the peer review. But
the role has been clearly explained by Dr.Hardisty, this role
is to be sure that we have detected the correct no adverse
effect level, that we have not missed a target tissue. Since
this is a positive influence, and because all of our companies
are responsible, we understand the issue and we want to do
good science. It is why we have to do it. We are responsible.
This peer review must be a positive input to the study. We
have to select, even for sponsor peer reviews, the pathologist
who can positively influence this review. Positively means
to bring more accuracy and more security to a difficult
process in the toxicology studies.
Dr. Oishi: While it is my personal opinion, if we assume that
any person is capable of wrongdoing, no regulation may be
able to prevent such wrongdoing. And yet, if we were to take
that stance and maintain the assumption that pathologists of
the manufacturers have a tendency of working to induce
profits for the manufacturers, I believe that the GLP
institution authentication to facilities in the manufacturers is
extremely paradoxical. Since the pathologists at the
manufacturers actually take full charge when conducting in-
house studies, I think that the discussion of the pressure from
the sponsors (manufacturers) being a hindrance of peer
reviews would lead to the question on the presence of a
stronger bias for in-house studies conducted at the
manufacturers.
When I first heard about the instructions of PDMA,
personally I was greatly devastated and angry with the
thinking that there was someone who would sell out his/her
heart among us pathologists. I was very much in shock at the
time when the authority said that pathologists of the sponsors
have a possibility to lead a CRO to a guided conclusion
beneficial to the sponsor. I still remember feeling really
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pathologists like this one, what we end up with is the need
for discussions among us pathologists. Communication
among the pathologists was extremely valuable and also
essential for us to improve our skills which I mentioned in
the last session this past year and wish to reiterate again here.
I truly believe this is the case.
I would like to have engaged in a more heated debate
despite the little time we had today, but the time is up for us
soon. Therefore, I would like to start wrapping up. Basically
the Japanese Society of Toxicologic Pathology has already
stated its full support to the STP position paper. There are
quite a number of points which challenge the instructions
given by the Japanese authority at this point. While we have
stated that we agree with the position paper as the Japanese
Society of Toxicologic Pathology, I am very much interested
in how everyone will actually engage in the topics we
discussed today after you go home, especially what kind of
stance those of you from the corporations will take.  GLP
inspection is scheduled two weeks later at our laboratory, but
I am hoping that things will turn out better in this area and
that everyone will work hard and take full responsibility over
the items they are evaluating so that the integrity of the
pathologists will not be brought to question.
As for the digital data discussed in the first half of this
session, I worry that the definition of “raw data” will be
extremely ambiguous if the Society of Toxicologic
Pathology of each country will not take seriously the line
drawn that basically image data that do not serve as the base
of a data are not raw data. I believe that various publications
on this topic will be released from the department in charge
of regulatory matters at the IFSTP. As Dr. Manabe is in
charge of the matter, if you have any opinions or
suggestions, we would greatly appreciate it if you would
contact Dr. Manabe or the Secretariat of the Japanese
Society of Toxicologic Pathology. Although it was a
compiled discussion today due in spite of tight schedule,
thank you very much for your participation. That is all, thank
you very much.